Maiwei Biotech announced that at the 2026 European Society of Medical Oncology Conference to be held from October 23 to October 27, 2026, the company will announce phase II clinical research data targeting the Nectin-4 ADC innovative drug 9MW2821 for patients with locally advanced or metastatic triple-negative breast cancer who have previously received ADC treatment with topoisomerase I inhibitors. As of April 10, 2026, of the 60 patients whose efficacy could be assessed, the objective remission rate was 30.0%, the disease control rate was 80.0%, the median progression-free survival was 3.7 months, the median duration of remission was 8.7 months, the median overall survival period was not mature, and no new safety signals were observed during follow-up. There is still uncertainty about whether the drug will be approved for marketing.
Zhitongcaijing · 1d ago
Share
Listen to the news
Maiwei Biotech announced that at the 2026 European Society of Medical Oncology Conference to be held from October 23 to October 27, 2026, the company will announce phase II clinical research data targeting the Nectin-4 ADC innovative drug 9MW2821 for patients with locally advanced or metastatic triple-negative breast cancer who have previously received ADC treatment with topoisomerase I inhibitors. As of April 10, 2026, of the 60 patients whose efficacy could be assessed, the objective remission rate was 30.0%, the disease control rate was 80.0%, the median progression-free survival was 3.7 months, the median duration of remission was 8.7 months, the median overall survival period was not mature, and no new safety signals were observed during follow-up. There is still uncertainty about whether the drug will be approved for marketing.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending